21 results on '"Wong, Matthew J."'
Search Results
2. Supplementary Methods, Figure Legends 1-6 from Ponatinib (AP24534), a Multitargeted Pan-FGFR Inhibitor with Activity in Multiple FGFR-Amplified or Mutated Cancer Models
3. SGX393 Inhibits the CML Mutant ${\rm Bcr}\text{-}{\rm Abl}^{{\rm T}315{\rm I}}$ and Preempts in vitro Resistance When Combined with Nilotinib or Dasatinib
4. SGX393 inhibits the CML mutant [Bcr-Abl.sup.T3151] and preempts in vitro resistance when combined with nilotinib or dasatinib
5. Activating alleles of JAK3 in acute megakaryoblastic leukemia
6. Design of an Eta-Phase Precipitation-Hardenable Nickel-Based Alloy with the Potential for Improved Creep Strength Above 1023 K (750 °C)
7. Abstract A29: Different PIK3CA activation mutations can lead to distinct signaling mechanisms and EGFR inhibitor sensitivities in colorectal cancer cells
8. Abstract 853: Ponatinib, a potent pan-BCR-ABL inhibitor, retains activity against gatekeeper mutants of FLT3, RET, KIT, PDGFRα/β and FGFR1
9. Ponatinib (AP24534), a Multitargeted Pan-FGFR Inhibitor with Activity in Multiple FGFR-Amplified or Mutated Cancer Models
10. Potent Activity of Ponatinib (AP24534) in Models of FLT3-Driven Acute Myeloid Leukemia and Other Hematologic Malignancies
11. Abstract 3560: Ponatinib (AP24534), a potent pan-FGFR inhibitor with activity in multiple FGFR-driven cancer models
12. DEVELOPMENT OF PRECIPITATION HARDENABLE AL-SC-ZR-HF QUATERNARY ALLOYS THROUGH THERMODYNAMIC MODELING, AND ROOM-TEMPERATURE AND ELEVATED TEMPERATURE HARDNESS
13. Abstract B259: Combined targeting of FGFR2 and mTOR by AP24534 and ridaforolimus results in synergistic antitumor activity in FGFR2‐driven endometrial cancer models
14. SGX393 inhibits the CML mutant Bcr-Abl T315I and preempts in vitro resistance when combined with nilotinib or dasatinib
15. SGX70393 Inhibits Bcr-AblT315I In Vitro and In Vivo and Completely Suppresses Resistance When Combined with Nilotinib or Dasatinib.
16. Inhibition of T315I Bcr-Abl and Other Imatinib-Resistant Bcr-Abl Mutants by the Selective Abl Kinase Inhibitor SGX70393.
17. In Chronic Myeloid Leukemia (CML) Patients with Complete Cytogenetic Response to Imatinib, BCR-ABL Kinase Domain Mutations Are Relatively Rare and Not Consistently Associated with Subsequent Relapse.
18. SGX393 inhibits the CML mutant Bcr-AblT1315I and preempts in vitro resistance when combined with nilotinib or dasatinib.
19. SGX70393 Inhibits Bcr-AblT315I In Vitro and In Vivo and Completely Suppresses Resistance When Combined with Nilotinib or Dasatinib.
20. Inhibition of T315I Bcr-Abl and Other Imatinib-Resistant Bcr-Abl Mutants by the Selective Abl Kinase Inhibitor SGX70393.
21. SGX70393 Inhibits Bcr-AblT315IIn Vitro and In Vivo and Completely Suppresses Resistance When Combined with Nilotinib or Dasatinib.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.